Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs-Reference-Cited by-同舟云学术

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs

Published:2017-11-22 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Paolucci Stefania,Premoli Marta,Novati Stefano,Gulminetti Roberto,Maserati Renato,Barbarini Giorgio,Sacchi Paolo,Piralla Antonio,Sassera Davide,De Marco Leone,Girello Alessia,Mondelli Mario U.,Baldanti Fausto

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-15987-1.pdf

Reference35 articles.

1. WHO Guidelines on Hepatitis B and C Testing Geneva: World Health Organization; Feb.ISBN-13: 978-92-4-154998-1 (2017).

2. Messina, J. P. et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61, 77–87 (2015).

3. Deterding, K. et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect. Dis. 13, 497–506 (2013).

4. Sarrazin, C. J. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J. Hepatol. 64, 486–504 (2016).

5. Benítez-Gutiérrez, L. et al. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin. Pharmacother. 17, 1215–23 (2016).

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular characterization of the nonstructural 5A (NS5A) region of hepatitis C virus in Thai blood donors;Archives of Microbiology;2024-04-15

2. Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis;Nature Communications;2023-11-17

3. Investigation of novel HCV therapies: Boscia angustifalia & Boscia senegalensis extracts loaded on galactosylated chitosan nanoparticles synthesized by eco-friendly method for HCV treatment;International Journal of Biological Macromolecules;2023-08

4. Pre‐existing, treatment‐specific resistance‐associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct‐acting antivirals;APMIS;2023-06-25

5. Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges;Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives;2023-01